Last reviewed · How we verify
NCT03381235
Exercise and RP (AVAMC and Emory)
NA trial testing Spin exercise in Retinitis Pigmentosa in 4 participants. Completed in 28 November 2018.
28 November 2018
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 4 |
| Start date | 23 February 2018 |
| Primary completion | 28 November 2018 |
| Estimated completion | 28 November 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Spin exercise
Conditions studied
- Retinitis Pigmentosa — all drugs for Retinitis Pigmentosa →
Sponsor
Emory University
Who can join
Adults 18 to 60, any sex, with Retinitis Pigmentosa. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to look in humans at the relationship between moderate or little exercise and their potential effects on the retina in patients with Retinitis Pigmentosa (RP).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Rescuing cones and daylight vision in retinitis pigmentosa mice.
Guadagni V, Biagioni M, Novelli E, Aretini P, et al · · 2019 · cited 31× · PMID 31199887 · DOI 10.1096/fj.201900414r
Verify or expand the search:
- PubMed search for NCT03381235
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Retinitis Pigmentosa
Currently open trials in the same condition.
- NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years · Phase 1, PHASE2 · recruiting
- NCT07408232 — A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) · Phase 1, PHASE2 · recruiting
- NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06936787 — An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa · Phase 1 · recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03381235 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 26 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03381235.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing